drugset / Trial / NCT06327100
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2029-05-01
- Completion
- 2031-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tasquinimod | Small molecule | — | Oral |
| Background | Ruxolitinib | Small molecule | — | Oral |